Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire completes acquisition of Dyax

Shire completes acquisition of Dyax

25th January 2016

Shire has announced the completion of its takeover of fellow healthcare company Dyax in a deal worth $5.9 billion (4.14 billion pounds).

The agreement, which was originally announced in November 2015, has now been finalised, allowing Shire to expand its expertise in the field of hereditary angioedema (HAE) treatment, an area in which Dyax specialises.

With this purchase, Shire will be able to add products such as Kalbitor and DX-2930 to its portfolio, while also benefiting from Dyax's commercial and research and development expertise.

Kalbitor is already approved for the treatment of HAE in patients aged 12 years and older, while DX-2930 is currently in development and could generate estimated annual global sales of up to $2 billion if approved.

Flemming Ornskov, Shire's chief executive officer, said: "We are excited to complete the acquisition of Dyax and look forward to working alongside their very talented and committed team to address significant unmet patient need around the world."

This comes as part of Shire's broader strategy of becoming a market leader in the treatment of rare diseases, as evidenced by its recent decision to pursue a merger with Baxalta.ADNFCR-8000103-ID-801810822-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.